Home/ Shop/ Weight Management/ TIRZEPATIDE Peptide 10-20 MG

Weight Management

TIRZEPATIDE Peptide 10-20 MG

Tirzepatide · 10MG or 20MG · GLP-1/GIP

99,00 €

Dose

Quantity

99,00 €

1 - 2 vials

89,10 € (10% off)

3 - 4 vials

84,15 € (15% off)

5+ vials

≥99% purity by HPLC
Janoshik COA with every lot
Lot-traceable from synthesis
EU-synthesised

In stock · Lot NZM-W-0019 · ships in 3–5 working days (EU)

Available for research procurement. Supplied as a lyophilized research compound with lot-specific COA.

Specifications

Lot NumberNZM-W-0019

Purity99.6% (HPLC)

Verified byJanoshik Analytical

Synthesis Date2026-04-08

FormLyophilized powder

StorageBelow 16°C · sealed

Third Party Lab Tested

Every lot is independently HPLC-tested by Janoshik Analytical, Europe's reference laboratory for peptide purity assessment. The COA shipped with your order is theirs, not ours.

Storage & Handling

Lyophilized peptides should be stored below 16°C, protected from light and moisture, for up to 24 months. Once reconstituted, refrigerate and use within 30 days for protocol consistency.

FormLyophilized powder

StorageLyophilized: below 16°C for up to 24 months. Reconstituted: refrigerate, use within 30 days.

Reconstitution

Reconstitute with bacteriostatic water using the volumes below. Add solvent slowly along the inside wall of the vial. Swirl gently, never shake, until fully dissolved.

Lab-handling protocol BAC Water · 0.9% benzyl alcohol The reconstitution solvent referenced above. Add to order →

Researched Benefits

Weight Reduction up to 22.5% Mean body-weight reduction at 72 weeks in highest published study arm. Glycemic Control A1C ↓ 1.9–2.6% HbA1c reduction in the SURPASS reference literature. Liver Fat Reduction up to 73% MASLD-substudy MRI-PDFF reduction at 52 weeks. Metabolic Flexibility Improved HOMA-IR and insulin-sensitivity markers improve monotonically across published study arms.

Product details

Dual-receptor incretin research.

Tirzepatide is a 39-amino-acid synthetic peptide characterised as a dual agonist at the GLP-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR). This two-receptor profile places Tirzepatide between single-pathway Semaglutide and triple-agonist Retatrutide in incretin and metabolic-signalling research. This variable product supplies 10 MG or 20 MG lyophilized research vials within the NZM-Labs research peptide range.

Every production lot is independently analysed by HPLC and mass spectrometry, with lot-specific documentation available for matching the vial to its analytical record. For laboratory research only.

Compound Specs

Research specification table for TIRZEPATIDE Peptide 10-20 MG
Compound	Tirzepatide
Sequence length	39 amino acids
Molecular mass	4813.5 Da
Modeled half-life	~5 days (modeled)
Mechanism / research class	Dual GLP-1R / GIPR agonist
Example laboratory preparation	10 MG or 20 MG vial with 2 mL bacteriostatic water (0.9% benzyl alcohol)
Calculated concentration	10 MG: 5 mg per 1.0 mL; 20 MG: 10 mg per 1.0 mL
Supply format	Tirzepatide · 10 MG or 20 MG lyophilized research vial
Storage, lyophilized	store below 16°C for up to 24 months
Storage, reconstituted	refrigerate and use within 30 days

Quality standards

Synthesised.
Verified.
Documented.

Wireframe rendering of a research peptide vial alongside molecular structure

Verified Purity

Every lot HPLC-tested by Janoshik Analytical. Independent verification, never in-house only. Current lot: 99.6% (HPLC).

Mass-Spec Confirmed

Identity confirmed by mass spectrometry. Theoretical mass matches measured within 0.5 Da tolerance.

Lyophilized & Sealed

Supplied as lyophilized powder in a sealed crimp-cap vial for laboratory handling and storage.

Lot-Traceable

From synthesis batch to your delivery, every step is logged. Search lot NZM-W-0019 for full traceability.

Evidence base

Backed by research.
Measured in results.

Each tag opens the cited literature behind that effect. References are linked to PubMed.

up to 22.5%

Weight Reduction

Tirzepatide is a 39-amino-acid GLP-1 / GIP dual agonist. The dual receptor profile produces a steeper satiety-pathway response than single-pathway GLP-1, with downstream effects on body weight and adiposity in both research models and published clinical literature.

The reference SURMOUNT-1 trial reported a mean body-weight reduction of −22.5% from baseline at 72 weeks in the highest published study arm, with monotonic responses across published study arms. Results referenced for in-vitro / animal-model protocol design only.

References

Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. NEJM. 2022;387(3):205-216. PubMed ↗
Frías JP et al. Tirzepatide vs Semaglutide once weekly in patients with type 2 diabetes. NEJM. 2021;385(6):503-515. PubMed ↗

A1C ↓ 1.9–2.6%

Glycemic Control

GLP-1 / GIP dual agonism amplifies insulin secretion and steepens the glycemic-response curve compared with single-pathway GLP-1 agonism. The reference literature reports HbA1c reductions of 1.87% to 2.59% across published weekly study arms in T2D research populations.

References

Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes. The Lancet. 2021;398(10295):143-155. PubMed ↗

up to 73%

Liver Fat Reduction

GLP-1 / GIP co-agonism engages hepatic lipid handling beyond what GLP-1 alone produces. The Tirzepatide MASLD substudy reported relative liver-fat reduction of up to 73% at 52 weeks measured by MRI-PDFF in the highest published study arm.

References

Hartman ML et al. Effects of tirzepatide on biomarkers of NAFLD/NASH in patients with T2D. Diabetes Care. 2020;43(6):1352-1355. PubMed ↗

Improved

Metabolic Flexibility

Beyond direct glycemic effects, dual incretin agonism improves measured markers of insulin sensitivity (HOMA-IR) and metabolic flexibility in research populations - a profile that distinguishes Tirzepatide from single-pathway references in published comparison studies.

References

Frías JP et al. SURPASS-2 trial. NEJM. 2021;385(6):503-515. PubMed ↗

Specific to TIRZEPATIDE Peptide 10-20 MG

Questions?
We have answers.

(01)

Why dual agonism and not single GLP-1?

Adding GIP-receptor activation amplifies the satiety and glycemic effect of GLP-1 without proportionally amplifying GI side effects. Most published metabolic-research protocols using dual-pathway compounds reference Tirzepatide as the canonical example.

(02)

How is the Certificate of Analysis verified?

Every lot is sent to Janoshik Analytical for independent HPLC and mass spectrometry testing. The COA you receive is theirs, not ours - searchable by lot number on our Science page, no account required.

(03)

How is the product shipped?

Lyophilized vials are shipped across the EU. Store sealed vials below 16°C after delivery. Typical delivery takes 3–5 working days.

(04)

Is this a research product?

Yes. NZM peptides are sold strictly for in vitro and animal research use only. They are not for human consumption, off-label use, or clinical application. Please consult applicable local regulations before ordering.

(05)

What is the Tirzepatide research peptide price?

The current Tirzepatide price is shown on this page. Pricing applies to B2B research procurement only and may vary by lot, format, and availability.

(06)

Can research customers buy Tirzepatide from NZM-Labs?

Yes. Research customers can order Tirzepatide through NZM-Labs for in vitro and animal research use only. It is not sold for human consumption, clinical use, or self-administration.

Researcher reviews